
Hetty Bontkes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4101288/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients. Blood Advances, 2022, 6, 1537-1546.	5.2	45
2	Neuroimmune responses following joint mobilisation and manipulation in people with persistent neck pain: a protocol for a randomised placebo-controlled trial. BMJ Open, 2022, 12, e055748.	1.9	2
3	MO663: No Translocation of Intact Intestinal Bacteria During Intermittent Dialysis Therapies. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
4	Accuracy of a no-biopsy approach for the diagnosis of coeliac disease across different adult cohorts. Gut, 2021, 70, 876-883.	12.1	81
5	Immune-mediated enteropathies: From bench to bedside. Journal of Autoimmunity, 2021, 118, 102609.	6.5	9
6	Distinct cellular immune profiles in the airways and blood of critically ill patients with COVID-19. Thorax, 2021, 76, 1010-1019.	5.6	53
7	Enrichment of CCR6 ⁺ CD8 ⁺ T cells and CCL20 in the lungs of mechanically ventilated patients with COVIDâ€19. European Journal of Immunology, 2021, 51, 1535-1538.	2.9	24
8	Effects of physical exercise on natural killer cell activity during (neo)adjuvant chemotherapy: A randomized pilot study. Physiological Reports, 2021, 9, e14919.	1.7	13
9	Patch test–relevant concentrations of metal salts cause localized cytotoxicity, including apoptosis, in skin ex vivo. Contact Dermatitis, 2021, 85, 531-542.	1.4	4
10	Adult-Onset Autoimmune Enteropathy in an European Tertiary Referral Center. Clinical and Translational Gastroenterology, 2021, 12, e00387.	2.5	8
11	The impact of the COVID-19 pandemic on autoimmune diagnostics in Europe: A lesson to be learned. Autoimmunity Reviews, 2021, 20, 102985.	5.8	7
12	Pre-analytical sample handling effects on blood cytokine levels: quality control of a COVID-19 biobank. Biomarkers in Medicine, 2021, 15, 987-997.	1.4	1
13	Non–heat inactivated autologous serum increases accuracy of in vitro CFSE lymphocyte proliferation test (LPT) for nickel. Clinical and Experimental Allergy, 2020, 50, 722-732.	2.9	8
14	Preliminary Notes on Equine Tissue Transglutaminase Serology and A Case of Equine Gluten-Sensitive Enteropathy and Dermatitis in an 11-Year-Old Dutch Warmblood Horse. Journal of Equine Veterinary Science, 2020, 90, 102999.	0.9	3
15	Increased IgA Glycoprotein-2 Specic Antibody Titres in Refractory Celiac Disease. Journal of Gastrointestinal and Liver Diseases, 2020, 23, 127-133.	0.9	15
16	Gamma-Delta T Lymphocytes in the Diagnostic Approach of Coeliac Disease. Journal of Clinical Gastroenterology, 2019, 53, e208-e213.	2.2	24
17	Frequencies and clinical associations of myositis-related antibodies in The Netherlands: A one-year survey of all Dutch patients. Journal of Translational Autoimmunity, 2019, 2, 100013.	4.0	34
18	HLA-DQ Typing Kits in Diagnosis and Screening for Celiac Disease. Genetic Testing and Molecular Biomarkers, 2019, 23, 418-422.	0.7	2

#	Article	IF	CITATIONS
19	Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study. The Lancet Gastroenterology and Hepatology, 2019, 4, 960-970.	8.1	52
20	The effects of systemic treatment with aminobisphosphonates and statins on circulating Vγ9VÎ′2-T cells in patients with advanced cancer. Immunobiology, 2018, 223, 171-177.	1.9	4
21	A retrospective study on titanium sensitivity: Patch test materials and manifestations. Contact Dermatitis, 2018, 79, 85-90.	1.4	33
22	Multiple confounders influence the association between low-grade systemic inflammation and musculoskeletal pain. A call for a prudent interpretation of the literature. Spine Journal, 2018, 18, 2162-2163.	1.3	12
23	Survival, Retention, and Selective Proliferation of Lymphocytes Is Mediated by Gingival Fibroblasts. Frontiers in Immunology, 2018, 9, 1725.	4.8	21
24	Human Bone Marrow-Derived Myeloid Dendritic Cells Show an Immature Transcriptional and Functional Profile Compared to Their Peripheral Blood Counterparts and Separate from Slan+ Non-Classical Monocytes. Frontiers in Immunology, 2018, 9, 1619.	4.8	16
25	Lymphoma development and survival in refractory coeliac disease type II: Histological response as prognostic factor. United European Gastroenterology Journal, 2017, 5, 208-217.	3.8	25
26	Outcome of Referrals for Non-Responsive Celiac Disease in a Tertiary Center: Low Incidence of Refractory Celiac Disease in the Netherlands. Clinical and Translational Gastroenterology, 2017, 8, e218.	2.5	30
27	Self-reported oral health and xerostomia in adult patients with celiac disease versus a comparison group. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2017, 124, 152-156.	0.4	11
28	Transcriptional profiling reveals functional dichotomy between human slan+non-classical monocytes and myeloid dendritic cells. Journal of Leukocyte Biology, 2017, 102, 1055-1068.	3.3	40
29	High myeloidâ€derived suppressor cell frequencies in the duodenum are associated with enteropathy associated Tâ€cell lymphoma and its precursor lesions. British Journal of Haematology, 2017, 178, 988-991.	2.5	4
30	A tandem approach of tTGA testing: A new approach for celiac disease screening. Indian Journal of Gastroenterology, 2017, 36, 443-444.	1.4	0
31	Screening for coeliac disease in adult patients with type 1 diabetes mellitus: myths, facts and controversy. Diabetology and Metabolic Syndrome, 2016, 8, 51.	2.7	15
32	The type I interferon signature in leukocyte subsets from peripheral blood of patients with early arthritis: a major contribution by granulocytes. Arthritis Research and Therapy, 2016, 18, 165.	3.5	38
33	Changes in peripheral blood lymphocyte subsets during arthritis development in arthralgia patients. Arthritis Research and Therapy, 2016, 18, 205.	3.5	26
34	Metal ions potentiate microglia responsiveness to endotoxin. Journal of Neuroimmunology, 2016, 291, 89-95.	2.3	4
35	Novel variant of EATL evolving from mucosal γÎ^T-cells in a patient with type I RCD. BMJ Open Gastroenterology, 2015, 2, e000026.	2.7	9
36	A Human Cell Line Model for Interferon-α Driven Dendritic Cell Differentiation. PLoS ONE, 2015, 10, e0135219.	2.5	1

#	Article	IF	CITATIONS
37	Innate stimulatory capacity of high molecular weight transition metals Au (gold) and Hg (mercury). Toxicology in Vitro, 2015, 29, 363-369.	2.4	18
38	B cell signature contributes to the prediction of RA development in patients with arthralgia. Annals of the Rheumatic Diseases, 2015, 74, 1786-1788.	0.9	19
39	Differential capacity of human interleukin-4 and interferon-α monocyte-derived dendritic cells for cross-presentation of free versus cell-associated antigen. Cancer Immunology, Immunotherapy, 2015, 64, 1419-1427.	4.2	12
40	Dendritic Cell Subsets in Bone Marrow and Peripheral Blood of Patients with Myelodysplastic Syndromes Display Numeric and Functional Defects. Blood, 2015, 126, 4109-4109.	1.4	0
41	Optimal Strategies to Identify Aberrant Intra-Epithelial Lymphocytes in Refractory Coeliac Disease. Journal of Clinical Immunology, 2014, 34, 828-835.	3.8	49
42	In situloading of skin dendritic cells with apoptotic bleb-derived antigens for the induction of tumor-directed immunity. Oncolmmunology, 2014, 3, e946360.	4.6	5
43	Seroprevalence of celiac disease in patients with autoimmune hepatitis. European Journal of Gastroenterology and Hepatology, 2014, 26, 1104-1107.	1.6	29
44	Apoptotic blebs from leukemic cells as a preferred source of tumor-associated antigen for dendritic cell-based vaccines. Cancer Immunology, Immunotherapy, 2014, 63, 335-345.	4.2	34
45	Serum autoantibodies directed against transglutaminase-2 have a low avidity compared with alloantibodies against gliadin in coeliac disease. Clinical and Experimental Immunology, 2014, 177, 86-93.	2.6	5
46	Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients. Journal of Translational Medicine, 2013, 11, 152.	4.4	12
47	Targeting the acute myeloid leukemic stem cell compartment by enhancing tumor cell-based vaccines. Immunotherapy, 2013, 5, 859-868.	2.0	8
48	Transition metal sensing by Tollâ€like receptorâ€4: next to nickel, cobalt and palladium are potent human dendritic cell stimulators. Contact Dermatitis, 2013, 68, 331-338.	1.4	109
49	Increased cytotoxic capacity of tumor antigen specific human T cells after in vitro stimulation with IL21 producing dendritic cells. Human Immunology, 2013, 74, 506-513.	2.4	10
50	Administration of anti-CD25 mAb leads to impaired α-galactosylceramide-mediated induction of IFN-γ production in a murine model. Immunobiology, 2013, 218, 851-859.	1.9	7
51	Dendritic cells in myelodysplastic syndromes: from pathogenesis to immunotherapy. Immunotherapy, 2013, 5, 621-637.	2.0	17
52	Procedures for the expansion of CD14+precursors from acute myeloid leukemic cells to facilitate dendritic cell-based immunotherapy. Immunotherapy, 2013, 5, 1183-1190.	2.0	2
53	Differential IL-13 Production by Small Intestinal Leukocytes in Active Coeliac Disease versus Refractory Coeliac Disease. Mediators of Inflammation, 2013, 2013, 1-8.	3.0	8
54	Effector memory Tâ€cell frequencies in relation to tumour stage, location and <scp>HPV</scp> status in <scp>HNSCC</scp> patients. Oral Diseases, 2013, 19, 577-584.	3.0	32

#	Article	IF	CITATIONS
55	Priming of PRAME- and WT1-specific CD8 ⁺ T cells in healthy donors but not in AML patients in complete remission. Oncolmmunology, 2013, 2, e23971.	4.6	15
56	Antibody titers against food antigens decrease upon a gluten-free diet, but are not useful for the follow-up of (refractory) celiac disease. European Journal of Gastroenterology and Hepatology, 2013, 25, 516-518.	1.6	4
57	Azacitidine differentially affects CD4pos T-cell polarization in vitro and in vivo in high risk myelodysplastic syndromes. Leukemia Research, 2012, 36, 921-930.	0.8	34
58	Clinical Trials with \hat{l} ±-Galactosylceramide (KRN7000) in Advanced Cancer. , 2012, , 169-183.		1
59	Role of immune responses in the pathogenesis of lowâ€risk MDS and highâ€risk MDS: implications for immunotherapy. British Journal of Haematology, 2011, 153, 568-581.	2.5	80
60	Targeting Toll-like receptor 7/8 enhances uptake of apoptotic leukemic cells by monocyte-derived dendritic cells but interferes with subsequent cytokine-induced maturation. Cancer Immunology, Immunotherapy, 2011, 60, 37-47.	4.2	14
61	High susceptibility of c-KIT+CD34+ precursors to prolonged doxorubicin exposure interferes with Langerhans cell differentiation in a human cell line model. Cancer Immunology, Immunotherapy, 2011, 60, 943-951.	4.2	6
62	Chronic myeloid leukemia lysate-loaded dendritic cells induce T-cell responses towards leukemia progenitor cells. Immunotherapy, 2011, 3, 569-576.	2.0	8
63	Attenuation of invariant Natural Killer T-cell anergy induction through intradermal delivery of α-galactosylceramide. Clinical Immunology, 2010, 136, 364-374.	3.2	24
64	Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia. Immunotherapy, 2010, 2, 69-83.	2.0	22
65	Immunomodulatory Effects of Azacitidine Treatment In High Risk Myelodysplastic Syndrome. Blood, 2010, 116, 1860-1860.	1.4	0
66	Apoptotic Blebs From Leukemic Cells as a Source of Tumor Associated Antigen for Monocyte-Derived Dendritic Cell Loading. Blood, 2010, 116, 3283-3283.	1.4	0
67	Expansion of AML Blasts Induces CD14 Expression and Facilitates Leukemic DC Development for Therapeutic Application In AML. Blood, 2010, 116, 2193-2193.	1.4	2
68	Azacitidine Induces A Shift In Th1/Th17 Ratio and FoxP3 Expression In Anti-CD3 Stimulated CD4+ T-Cells; Implications for the Treatment of Myelodysplastic Syndromes. Blood, 2010, 116, 4026-4026.	1.4	0
69	Differential indirect activation of human invariant natural killer T cells by Toll-like receptor agonists. Immunotherapy, 2009, 1, 557-570.	2.0	9
70	Maturation by Toll Like Receptor Ligand R848 Improves the Uptake of Apoptotic Leukemic Cells by Monocyte Derived Dendritic Cells Blood, 2009, 114, 2075-2075.	1.4	0
71	Functional PRAME Specific T Cells Can Be Cultured From CD8+ Cells From Healthy Donors but Not From Patients at First CR: Implications for Immunotherapeutic Strategies in AML Blood, 2009, 114, 4139-4139.	1.4	0
72	A Dendritic Cell Based Vaccination Strategy Geared towards Eradication of Leukemic Stem Cells Blood, 2009, 114, 2046-2046.	1.4	0

#	Article	IF	CITATIONS
73	Chronically stimulated mouse invariant NKT cell lines have a preserved capacity to enhance protection against experimental tumor metastases. Immunology Letters, 2008, 118, 36-43.	2.5	12
74	Decreased circulating iNKT cell numbers in refractory coeliac disease. Clinical Immunology, 2008, 126, 172-179.	3.2	18
75	Tumor associated antigen and interleukin-12 mRNA transfected dendritic cells enhance effector function of natural killer cells and antigen specific T-cells. Clinical Immunology, 2008, 127, 375-384.	3.2	51
76	In vitro expanded human invariant natural killer T-cells promote functional activity of natural killer cells. Clinical Immunology, 2008, 129, 145-154.	3.2	11
77	Invariant natural killer T cells and immunotherapy of cancer. Clinical Immunology, 2008, 129, 182-194.	3.2	32
78	Toll-like receptor agonists and invariant natural killer T-cells enhance antibody-dependent cell-mediated cytotoxicity (ADCC). Cancer Letters, 2008, 272, 70-76.	7.2	24
79	Inducing Antitumor T Cell Immunity: Comparative Functional Analysis of Interstitial Versus Langerhans Dendritic Cells in a Human Cell Line Model. Journal of Immunology, 2008, 180, 4540-4549.	0.8	43
80	IFN-γ-Producing Human Invariant NKT Cells Promote Tumor-Associated Antigen-Specific Cytotoxic T Cell Responses. Journal of Immunology, 2008, 181, 2446-2454.	0.8	48
81	Comparative Analysis of CD8+ t Cell Priming Efficiencies against a Panel of Leukemia-Associated HLA-A2 Restricted Epitopes Identifies PRAME as a Possible Vaccination Target in AML. Blood, 2008, 112, 5441-5441.	1.4	0
82	Phenotypical and Functional Characterization of Freshly Isolated Adipose Tissue-Derived Stem Cells. Stem Cells and Development, 2007, 16, 91-104.	2.1	273
83	Low Levels of Circulating Invariant Natural Killer T Cells Predict Poor Clinical Outcome in Patients With Head and Neck Squamous Cell Carcinoma. Journal of Clinical Oncology, 2007, 25, 862-868.	1.6	188
84	High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC). Cancer Letters, 2007, 257, 47-55.	7.2	46
85	CD4+CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia. International Journal of Cancer, 2007, 121, 1749-1755.	5.1	134
86	Dendritic cells transfected with interleukin-12 and tumor-associated antigen messenger RNA induce high avidity cytotoxic T cells. Gene Therapy, 2007, 14, 366-375.	4.5	71
87	Generation and sustained expansion of mouse spleen invariant NKT cell lines with preserved cytokine releasing capacity. Journal of Immunological Methods, 2007, 322, 70-81.	1.4	15
88	Constitutively Active STAT5b Induces Cytokine-Independent Growth of the Acute Myeloid Leukemia–Derived MUTZ-3 Cell Line and Accelerates Its Differentiation Into Mature Dendritic Cells. Journal of Immunotherapy, 2006, 29, 188-200.	2.4	17
89	Cutting Edge: Rapid Recovery of NKT Cells upon Institution of Highly Active Antiretroviral Therapy for HIV-1 Infection. Journal of Immunology, 2006, 177, 5775-5778.	0.8	51
90	Plasmacytoid dendritic cells are present in cervical carcinoma and become activated by human papillomavirus type 16 virus-like particles. Gynecologic Oncology, 2005, 96, 897-901.	1.4	43

#	Article	IF	CITATIONS
91	Interleukin-12 Increases Proliferation and Interferon-Î ³ Production but Not Cytolytic Activity of Human Antigen-Specific Effector Memory Cytotoxic T Lymphocytes: Power of the Effect Depends on the Functional Avidity of the T Cell and the Antigen Concentration. Human Immunology, 2005, 66, 1137-1145.	2.4	9
92	Antigen Gene Transfer to Human Plasmacytoid Dendritic Cells Using Recombinant Adenovirus and Vaccinia Virus Vectors. Analytical Cellular Pathology, 2005, 27, 175-182.	1.4	5
93	Expansion of dendritic cell precursors from human CD34(+) progenitor cells isolated from healthy donor blood; growth factor combination determines proliferation rate and functional outcome. Journal of Leukocyte Biology, 2002, 72, 321-9.	3.3	34
94	Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia. International Journal of Cancer, 2000, 88, 92-98.	5.1	79
95	Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia. International Journal of Cancer, 2000, 88, 92-8.	5.1	21
96	Expression of CD3-ζ on T-cells in primary cervical carcinoma and in metastasis-positive and -negative pelvic lymph nodes. British Journal of Cancer, 1999, 79, 1127-1132.	6.4	31
97	Differences in cytokine mRNA profiles between premalignant and malignant lesions of the uterine cervix. European Journal of Cancer, 1999, 35, 490-497.	2.8	55
98	Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome Journal of General Virology, 1999, 80, 399-408.	2.9	57
99	Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16 Journal of General Virology, 1999, 80, 409-417.	2.9	99
100	Human papillomavirus type 16 E2-specific T-helper lymphocyte responses in patients with cervical intraepithelial neoplasia. Journal of General Virology, 1999, 80, 2453-2459.	2.9	36
101	HPV 16 infection and progression of cervical intra-epithelial neoplasia: Analysis of HLA polymorphism and HPV 16 E6 sequence variants. International Journal of Cancer, 1998, 78, 166-171.	5.1	94
102	Specific HLA class I down-regulation is an early event in cervical dysplasia associated with clinical progression. Lancet, The, 1998, 351, 187-188.	13.7	95
103	Differential T helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia: a longitudinal study. Cancer Research, 1998, 58, 1700-6.	0.9	79
104	Immunoglobulin G Responses Against Human Papillomavirus Type 16 Virus-Like Particles in a Prospective Nonintervention Cohort Study of Women With Cervical Intraepithelial Neoplasia. Journal of the National Cancer Institute, 1997, 89, 630-638.	6.3	83
105	Assessment of cytotoxic T-lymphocyte phenotype using the specific markers granzyme B and TIA-1 in cervical neoplastic lesions. British Journal of Cancer, 1997, 76, 1353-1360.	6.4	47
106	Analysis of IgG reactivity against human papillomavirus type-16 E7 in patients with cervical intraepithelial neoplasm indicates an association with clearance of viral infection: results of a prospective study. , 1996, 68, 731-738.		25
107	T Cell Proliferative Responses Against Human Papillomavirus Type 16 E7 Oncoprotein are Most Prominent in Cervical Intraepithelial Neoplasia Patients with a Persistent Viral Infection. Journal of General Virology, 1996, 77, 2183-2191.	2.9	61
108	IgG Subclass Response toHelicobacter pyloriin Patients with Chronic Active Gastritis and Duodenal Ulcer. Scandinavian Journal of Gastroenterology, 1992, 27, 129-133.	1.5	29